Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.

Committee Composition

HH Sheikh Abdullah bin Khalifa Al Thani
Elected 2012

His Highness Sheikh Abdullah bin Khalifa Al Thani has served as Special Advisor to the Emir since his appointment in April 2007, and was Prime Minister of Qatar from October 1996 to April 2007. His Highness has served as Chairman of the board of directors of Qatar Investment and Projects Development Holding Company, a Qatari investment group, since March 2011 and as Chairman of the board of directors of Specialized International Services (SIS) Qatar, a business investment company, since October 2011. His Highness graduated from the Royal Military Academy Sandhurst.

Recent Stock Transactions by HH Sheikh Abdullah bin Khalifa Al Thani
Date Type Shares Traded Price Range
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Mar 27, 2013 Buy 1,533,742 3.26
Dec 24, 2012 Buy 3,355,704 2.98
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Mar 15, 2012 Statement of Ownership 0 n/a
Christophe Vuillez

Christophe Vuillez is a Senior Vice President, and the Head of Strategy, Development and Research of the Refining & Chemicals division, of Total S.A., one of the world’s largest energy companies. Mr. Vuillez has piloted a number of M&A projects for the Refining & Chemicals division, and he is also a longstanding member of the supervisory committee for Total’s venture capital activities. Mr. Vuillez has nearly 30 years of international experience in the various stages of diverse technological, industrial and corporate development and strategy: from leading and managing applied R&D in the aerospace industry, managing the construction and operation of complex industrial facilities in the oil and gas industry, to holding different executive positions throughout the growth and development of a French telecom from being a startup through its becoming a major player in the industry. Mr. Vuillez holds an advanced degree in aerospace science and technologies from the Ecole Supérieure de l’Aéronautique et de l’Espace in Toulouse, France, which he obtained after graduating from the prestigious French Ecole Polytechnique.

John Doerr
Elected 2006

John Doerr is a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the board of directors of Amazon.com, Inc. Mr. Doerr holds Bachelor of Science and Master of Science in Electrical Engineering degrees from Rice University and a Master of Business Administration degree from Harvard University.

Recent Stock Transactions by John Doerr
Date Type Shares Traded Price Range
May 11, 2017 Disposition (Non Open Market) 13,037,586 1.00
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jun 14, 2016 Buy 200,577 1.04
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Jul 29, 2015 Buy 9,615,384 1.56
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
May 15, 2014 Buy 172,186 3.02
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
May 24, 2013 Buy 24,402 2.85
Dec 24, 2012 Buy 1,677,852 2.98
Aug 31, 2012 Buy 270,270 3.70
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
May 18, 2012 Buy 211,864 2.36
Feb 23, 2012 Acquisition (Non Open Market) 865,051 5.78
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
Jun 2, 2011 Acquisition (Non Open Market) 8,503 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,594,605 n/a
Sep 30, 2010 Acquisition (Non Open Market) 66,297 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,660,902 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,800,587 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Geoffrey Duyk M.D., Ph.D
Elected 2012

Dr. Geoffrey Duyk was a member of the Board from May 2006 through May 2011, and re-joined the Board in May 2012. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P. and a partner and managing director of TPG ART.  Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of Aerie Pharmaceuticals, Inc. and EPIRUS Biopharmaceuticals, Inc., as well as several private companies and the non-profit Case Western Reserve University Board of Trustees and the American Society of Human Genetics Board of Directors. He served on the board of directors of Agria Corporation from August 2007 to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003, as well as the Wesleyan University Board of Trustees from 2008 to June 2014. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University.

Recent Stock Transactions by Geoffrey Duyk M.D., Ph.D
Date Type Shares Traded Price Range
Nov 3, 2016 Acquisition (Non Open Market) 35,000 n/a
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
May 4, 2012 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Philip Eykerman

Mr. Eykerman joined DSM in 2011 as Executive Vice-President, Corporate Strategy & Acquisitions. In this role, he is responsible for corporate and business group strategy development, budgeting and planning, improvement programs, and all M&A activities. In 2015, he was also appointed as a member of the DSM Executive Committee and at present is responsible for the Pharmaceuticals as well as DSM Food Specialties activities. Next to these roles within DSM, he is also a member of the Supervisory Board of Patheon N.V., a Supervisory Board member of DSM Sinochem Pharmaceuticals (DSM/Sinochem JV), and a Supervisory Board member of ChemicaInvest (DSM/CVC JV). Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 year as a Partner and leader of McKinsey’s Chemicals Practice in the Benelux and France. He holds a master degree in Chemical Engineering from the KU Leuven (Belgium) and in Refinery Engineering from the Institut Francais du Pétrole (France).

Bram Klaeijsen
Elected 2015

Bram Klaeijsen served as President and Regional Director, Asia-Pacific and platform leader for Cargill Food Ingredients and Systems, a division of Cargill, Inc., a position from which he retired in January 2015. Mr. Klaeijsen joined Cargill in 1978 and held a number of leadership positions, including as Platform Leader for Cargill’s European Food Ingredients businesses from 1999 to 2003, when he assumed the role of Executive Vice President of Cargill Food Ingredients and Systems. He held that position until he joined Cargill’s Asia-Pacific operations in 2009, where he served until his retirement.  Mr. Klaeijsen holds a Bachelor of Science degree in chemical engineering from technical college Breda in the Netherlands. 

Recent Stock Transactions by Bram Klaeijsen
Date Type Shares Traded Price Range
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
John Melo
Elected 2007

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Download Photo

Recent Stock Transactions by John Melo
Date Type Shares Traded Price Range
May 1, 2017 Disposition (Non Open Market) 53,238 0.52
Apr 1, 2017 Disposition (Non Open Market) 37,580 0.52
Nov 1, 2016 Disposition (Non Open Market) 37,580 1.06
Jun 14, 2016 Sell 200,577 1.04
Jun 1, 2016 Disposition (Non Open Market) 53,238 0.54
May 16, 2016 Acquisition (Non Open Market) 425,000 n/a
Apr 1, 2016 Disposition (Non Open Market) 67,518 1.09
Nov 9, 2015 Acquisition (Non Open Market) 300,000 n/a
Jun 8, 2015 Acquisition (Non Open Market) 425,000 n/a
Jun 5, 2015 Automatic Sell 20,440 1.96
Jun 4, 2015 Automatic Sell 20,418 2.00
Jun 3, 2015 Automatic Sell 20,418 2.04
May 12, 2015 Automatic Sell 20,440 2.04
May 11, 2015 Automatic Sell 20,418 2.04
May 8, 2015 Automatic Sell 24,717 2.15
Apr 1, 2015 Disposition (Non Open Market) 73,781 2.45
May 15, 2014 Sell 172,186 3.02
May 5, 2014 Acquisition (Non Open Market) 300,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 126,677 4.44
Jan 1, 2014 Disposition (Non Open Market) 3,363 4.71
Jun 3, 2013 Acquisition (Non Open Market) 239,000 n/a
May 24, 2013 Sell 24,402 2.85
Apr 1, 2013 Disposition (Non Open Market) 6,113 3.06
Jan 2, 2013 Disposition (Non Open Market) 3,364 3.20
Aug 31, 2012 Sell 553,730 3.70
Aug 31, 2012 Sell 115,000 3.70
Aug 31, 2012 Option Execute 553,730 0.28
Aug 31, 2012 Option Execute 115,000 0.28
May 15, 2012 Acquisition (Non Open Market) 3,273 1.53
Apr 9, 2012 Acquisition (Non Open Market) 250,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 3,225 12.27
Oct 10, 2011 Automatic Sell 20,000 17.22
Oct 10, 2011 Option Execute 20,000 0.28
Aug 10, 2011 Automatic Sell 27,500 20.02 - 20.67
Aug 10, 2011 Option Execute 27,500 0.28
Aug 9, 2011 Automatic Sell 23,800 19.66 - 20.44
Aug 9, 2011 Option Execute 23,800 0.28
Aug 8, 2011 Automatic Sell 18,500 20.04 - 20.55
Aug 8, 2011 Option Execute 18,500 0.28
Jul 8, 2011 Automatic Sell 6,000 28.28
Jul 8, 2011 Option Execute 6,000 0.28
Jul 7, 2011 Automatic Sell 7,000 27.97
Jul 7, 2011 Option Execute 7,000 0.28
Jul 6, 2011 Automatic Sell 4,500 28.21
Jul 6, 2011 Option Execute 4,500 0.28
Jul 5, 2011 Automatic Sell 8,000 27.89
Jul 5, 2011 Option Execute 8,000 0.28
Jul 1, 2011 Automatic Sell 19,970 28.05
Jul 1, 2011 Option Execute 19,970 0.28
Jun 30, 2011 Automatic Sell 11,900 28.19
Carole Piwnica
Elected 2009

Ms. Piwnica is Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a chairman of Amylum Group, a European food ingredient company and affiliate of Tate & Lyle Plc, from 1996 to 2000. From 1992 to 1996, Ms. Piwnica held general management positions and board memberships in various other European food companies, including Cacao Barry and Vital Sogéviandes. Ms. Piwnica was a member of the board of directors of Aviva plc, a British insurance company, from May 2003 to December 2011, a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009, a member of the board of directors of Dairy Crest from 2007 until 2010, and a member of the board of directors of Toepfer Gmbh from 1996 until 2010. In 2010, she was appointed as a member of the boards of Eutelsat (satellites, France) and Sanofi (pharmaceuticals, France). Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. She has also been a member of the bar association of the state of New York, USA since 1985.

Recent Stock Transactions by Carole Piwnica
Date Type Shares Traded Price Range
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
Fernando Reinach Ph.D.
Elected 2008

Dr. Fernando Reinach is managing partner of Pitanga Fund, a venture capital fund based in Brazil, since May 2011. From 2001 to May 2010, Dr. Reinach was a General Partner at Votorantim Novos Negócios Ltda. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach holds a Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College.

Recent Stock Transactions by Fernando Reinach Ph.D.
Date Type Shares Traded Price Range
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Dec 24, 2012 Buy 83,892 2.98
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Feb 23, 2012 Acquisition (Non Open Market) 86,505 5.78
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
Neil Williams
Elected 2013

R. Neil Williams has served as Intuit's Executive Vice President and Chief Financial Officer since January 2008. He is responsible for all financial aspects of Intuit, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Mr. Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for the company and its subsidiaries, including financial planning, business planning and financial monitoring. Williams concurrently served as Chief Financial Officer for Inovant LLC, Visa's global information technology organization, responsible for global transactions processing and technology development. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Williams, a certified public accountant, received his Bachelor's degree in business administration from the University of Southern Mississippi.

Recent Stock Transactions by Neil Williams
Date Type Shares Traded Price Range
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Patrick Yang Ph.D.
Elected 2014

Dr. Patrick Y. Yang was appointed to the Board of Amyris, effective July 1, 2014. From January 2010 to March 2013, he served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd. where he was responsible for the company's pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement. Before joining Roche, he worked for Genentech, Merck & Co., General Electric and Life Systems, during which time he developed significant experience with pharmaceuticals and biotechnology manufacturing, engineering, technology, and supply chain management. Dr. Yang currently serves on the board of directors of Tesoro Corporation, a public independent petroleum refining and marketing company, since December 2010; Codexis, a public company that develops biocatalysts for the pharmaceutical and fine chemicals markets, since February 2014; and PharmaEssentia Corporation, a clinical-stage biotechnology company, since March 2014; and previously served on the board of TaiMed, Inc. in 2007-2009; and Celladon Corporation in 2014-2015: both are clinical-stage biotechnology companies.  Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.

Recent Stock Transactions by Patrick Yang Ph.D.
Date Type Shares Traded Price Range
May 19, 2017 Buy 200,000 0.29 - 0.29
May 18, 2017 Buy 100,000 0.29
Jul 13, 2016 Acquisition (Non Open Market) 17,000 n/a
Jul 30, 2015 Acquisition (Non Open Market) 3,000 n/a
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Jul 1, 2014 Statement of Ownership 0 n/a

Stock transaction information provided by EDGAR Online. Amyris makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

  Audit Nominating and Governance Leadership Development and Compensation
John Doerr
Image of John Doerr
John Doerr
Director; and Chair of the Nominating and Governance Committee
Kleiner Perkins Caufield & Byers
Elected 2006

John Doerr is a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the board of directors of Amazon.com, Inc. Mr. Doerr holds Bachelor of Science and Master of Science in Electrical Engineering degrees from Rice University and a Master of Business Administration degree from Harvard University.

 
Geoffrey Duyk M.D., Ph.D
Image of Geoffrey Duyk M.D., Ph.D
Geoffrey Duyk M.D., Ph.D
Director; TPG Biotech
Elected 2012

Dr. Geoffrey Duyk was a member of the Board from May 2006 through May 2011, and re-joined the Board in May 2012. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P. and a partner and managing director of TPG ART.  Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of Aerie Pharmaceuticals, Inc. and EPIRUS Biopharmaceuticals, Inc., as well as several private companies and the non-profit Case Western Reserve University Board of Trustees and the American Society of Human Genetics Board of Directors. He served on the board of directors of Agria Corporation from August 2007 to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003, as well as the Wesleyan University Board of Trustees from 2008 to June 2014. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University.

   
Carole Piwnica
Image of Carole Piwnica
Carole Piwnica
Director; and Chair of the Leadership Development and Compensation Committee
Naxos
Elected 2009

Ms. Piwnica is Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a chairman of Amylum Group, a European food ingredient company and affiliate of Tate & Lyle Plc, from 1996 to 2000. From 1992 to 1996, Ms. Piwnica held general management positions and board memberships in various other European food companies, including Cacao Barry and Vital Sogéviandes. Ms. Piwnica was a member of the board of directors of Aviva plc, a British insurance company, from May 2003 to December 2011, a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009, a member of the board of directors of Dairy Crest from 2007 until 2010, and a member of the board of directors of Toepfer Gmbh from 1996 until 2010. In 2010, she was appointed as a member of the boards of Eutelsat (satellites, France) and Sanofi (pharmaceuticals, France). Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. She has also been a member of the bar association of the state of New York, USA since 1985.

 
Fernando Reinach Ph.D.
Image of Fernando Reinach Ph.D.
Fernando Reinach Ph.D.
Director; Pitanga
Elected 2008

Dr. Fernando Reinach is managing partner of Pitanga Fund, a venture capital fund based in Brazil, since May 2011. From 2001 to May 2010, Dr. Reinach was a General Partner at Votorantim Novos Negócios Ltda. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach holds a Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College.

   
Neil Williams
Image of Neil Williams
Neil Williams
Director; and Chair of the Audit Committee
Intuit, Inc.
Elected 2013

R. Neil Williams has served as Intuit's Executive Vice President and Chief Financial Officer since January 2008. He is responsible for all financial aspects of Intuit, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Mr. Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for the company and its subsidiaries, including financial planning, business planning and financial monitoring. Williams concurrently served as Chief Financial Officer for Inovant LLC, Visa's global information technology organization, responsible for global transactions processing and technology development. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Williams, a certified public accountant, received his Bachelor's degree in business administration from the University of Southern Mississippi.

   
= Chair = Member

Stock transaction information provided by EDGAR Online. Amyris makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.